Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06623422 · ClinicalTrials.gov registry record · Phase 3
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
A Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 680
- Enrollment target
- 20
- Study locations
NCT06623422 is a Phase 3 study of Carcinoma, Non-Small Cell Lung that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 680 participants, above the 319-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (113% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT06623422, a Phase 3 study of Carcinoma, Non-Small Cell Lung, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 680 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Gemcitabine
Study Locations (20)
California
- Providence St. Jude Medical Center ( Site 0106) - Fullerton
- VA Long Beach Healthcare System ( Site 0199) - Long Beach
- USC Norris Comprehensive Cancer Center ( Site 0205) - Los Angeles
- UCSF Medical Center at Mission Bay ( Site 0178) - San Francisco
Colorado
- University of Colorado Anschutz Medical Campus ( Site 0151) - Aurora
- UCHealth Memorial Hospital Central ( Site 0125) - Colorado Springs
- Banner MD Anderson Cancer Center at North Colorado Medical Center ( Site 0207) - Greeley
- Centura Health - St. Anthony North Health Campus ( Site 0189) - Westminster
Arizona
- Banner MD Anderson Cancer Center ( Site 0181) - Gilbert
- The University of Arizona Cancer Center - North Campus ( Site 0163) - Tucson
Connecticut
- Yale University School of Medicine ( Site 0201) - New Haven
- Eastern CT Hematology & Oncology Associates ( Site 0202) - Norwich
Florida
- The Oncology Institute of Hope and Innovation - Fort Lauderdale ( Site 0156) - Fort Lauderdale
- Miami Cancer Institute at Baptist Health, Inc. ( Site 0214) - Miami
Massachusetts
- Massachusetts General Hospital ( Site 0136) - Boston
- Dana Farber Cancer Hospital ( Site 0155) - Boston
Idaho
- Beacon Cancer Care ( Site 0127) - Post Falls
Illinois
- The University of Chicago Medical Center ( Site 0118) - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 680 participants |
| Start Date | 2024-10-21 |
| Est. Completion | 2038-01-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06623422
The ClinicalTrials.gov registry entry for NCT06623422 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 680 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 319-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (113% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06623422 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Colorado, Arizona.
Frequently Asked Questions
What is clinical trial NCT06623422 about?
NCT06623422 is a clinical study titled "A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)". The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer fr...
What is the current status of trial NCT06623422?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 680 participants. The study started on 2024-10-21. Estimated completion is 2038-01-26.
What conditions does trial NCT06623422 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT06623422?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT06623422?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06623422 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
-
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.